Advised by industry thought leaders
Partnering with us to Drive Change
Corporate Advisory Board
William E. Rhodes III
Chair, Founding Member, Third Day Advisors LLC
Bill Rhodes is Founding Member of Third Day Advisors LLC, a management and strategy advisory firm specializing in helping healthcare and life sciences companies as they consider corporate mergers and acquisitions as part of their growth plans. He is also an Operating Partner with Linden Capital Partners LP, a Chicago-based healthcare private equity firm, where he is responsible for the life sciences and diagnostics sector.
Prior, Mr. Rhodes was with Becton Dickinson and Co. (BD), a Fortune 500, multinational healthcare products corporation, as a named Executive Officer and the Senior Vice President, Business Development and Strategy. He was responsible for corporate strategy and global M&A activities.
Previous to this role, he served as BD’s Worldwide President, BD Biosciences, a 3,000 person, US $1.4 billion segment, responsible for its three business units: Cell Analysis, Discovery Labware and Advanced Bioprocessing. Prior to assuming that role, he was President, Cell Analysis, and before that, VP of Business Development and Strategic Investments, where he held worldwide responsibility for business development activities. He also formed and managed BD Ventures L.L.C., the corporate venture capital fund operated by BD.
Prior to joining BD, Mr. Rhodes held various senior executive roles in business development and technology, for Pfizer, Johnson and Johnson and The William James Company.
Mr. Rhodes also currently serves as Senior Executive in Residence at Cornell University, where he identifies university-based technologies appropriate for business formation, and mentors entrepreneurs. In addition, he is a Clinical Instructor with the Weill Cornell Medical College’s Department of Public Health.
John J. Wallace
Former Chief Operating Officer, Nova Biomedical Corporation
John Wallace is a results-oriented senior executive with over 30 years of global experience in management, operations, finance, international business and manufacturing. He has a diverse background and a proven track record of strong leadership.
Mr. Wallace was the Chief Operating Officer at Nova Biomedical Corporation, a world leader in the development, marketing and manufacture of proprietary blood diagnostic products, consumer healthcare diabetes products and medical devices for Fortune 500 and emerging companies. Nova is a pioneer in the development of biosensors for whole blood diagnostics to support the care of critically ill patients. With more than $175 million in revenue run rate and in excess of $35 million in operating profits, Nova was built by the strength and depth of its 750+ employees and sweat equity. Mr. Wallace led the management of strategic alliances and served on the Board of Directors, the Corporate Quality Committee and was the Chairman of the Operating Committee. Nova experienced consistent record revenue and earnings growth during his tenure.
Mr. Wallace has served on numerous Boards including on the Board of Directors and as Chairman of the Audit Committee of Zoll Medical Inc. (NASDAQ), a world leader in resuscitation and critical care devices. The Company experienced rapid market expansion and numerous product innovations during his involvement with Zoll. Mr. Wallace played an active role in the acquisition of Zoll by Japan’s Asahi Kasei Corporation in a $2.2 billion cash transaction where Zoll’s management and employees remained intact.
Earlier in his career, Mr. Wallace was a senior executive at Cortex Corporation as well as Numerix Corporation, and also held management positions with Analog Devices Inc., Data General Corporation and Federated Department Stores (Filene’s Division). Currently, Mr. Wallace holds Board positions with Triangle, Inc., Massachusetts Medical Device Industry Council (MassMedic), Discovering Justice/James D. St. Clair Federal Court Education Program, Neighborhood Association of the Back Bay and is a Senior Advisor to Tower Three Medical (an arm of Tower Three Partners – a Greenwich Connecticut-based private equity firm) in the role of Executive Vice President and Chief Operating Officer, where he provides guidance on evaluating potential acquisitions and financial/operational implementation and effectiveness.
Nathan A. McLemore
Managing Director, Columbia Pacific Management
Nate McLemore is a Managing Director for Columbia Pacific Management, where he is responsible for the firm’s healthcare investments with a primary focus on hospitals and senior housing in Asia. Mr. McLemore is a Board Member of Columbia Asia, a healthcare system with 23 hospitals and clinics in India, Indonesia, Malaysia, and Vietnam. He also serves on the Board of Remote Medical International , a medical and rescue services company specializing in providing care in remote areas. In China, Mr. McLemore is working to expand Kaijian Healthcare, the first foreign-owned operator of senior housing in the country, as well as pursuing several projects to build and operate hospitals.
Prior to joining Columbia Pacific, Mr. McLemore was a General Manager in Microsoft’s Health Solutions Group, where he was responsible for international sales, business development, M&A, professional services, policy and compliance. Mr. McLemore joined Microsoft from RelayHealth, where he served as Vice President of Business Development for this leader in online, doctor-patient communication, which was acquired by McKesson in 2006.
Earlier in his career, Mr. McLemore headed CFM’s federal lobbying practice, where he represented health care systems and technology companies before Congress and the Executive Branch. Mr. McLemore has a BA in Political Science from Willamette University and an MBA from the University of California at Berkeley’s Haas School of Business. He enjoys spending time with his wife and two young sons and is an avid skier, runner, boater, and an aspiring golfer.
Jack W. Krouskup
Former Partner-in-Charge Deloitte Northern California Financial Services Practice
Jack Krouskup has over 35 years of experience serving clients in a variety of industries. His primary focus over the past ten years was clients in the chemical manufacturing, healthcare and life sciences industries. Mr. Krouskup was previously partner-in-charge of Deloitte’s Northern California financial services practice where he served on Deloitte’s financial services advisory committee. He served as advisory partner on a number of large Northern California clients, and used his years of experience to support Deloitte teams and provide insights to client management and audit committees. Mr. Krouskup also helped lead an internal Deloitte integration team to effect an international merger of major accounting firms.
Mr. Krouskup has years of boardroom experience representing Deloitte with numerous global and highly complex organizations. Consequently, he has extensive corporate governance background and deep familiarity with board and audit committee best practices. Additionally, he has served numerous early stage companies in both financial services and life sciences including several IPO and merger transactions. He has broad experience in Securities and Exchange Commission (SEC) matters and other accounting and reporting requirements including initial public offerings, debt and equity registrations, responding to SEC comment letters and foreign statutory audit filings. Jack assisted several companies (including McKesson and Huntsman Corporations) in their initial year of compliance with internal controls related to financial reporting (Sarbanes 404).
Mr. Krouskup previously concentrated on financial services clients and served as a technical advisor to several financial services industry groups. He served as lead client service partner for the San Francisco Federal Home Loan Bank and also worked with Federal regulators on the liquidation/receivership audits of several failed institutions.
Mr. Krouskup’s extensive experience in the areas of mergers and acquisitions, including due diligence evaluations in financial services, healthcare and distribution sectors bring significant value Magnolia Medical Technologies.
Dennis F. Capovilla
Executive Director Powis Inc.
Dennis Capovilla is a Silicon Valley executive whose 25+ year career has included senior management positions at Fortune 100, microcap and startup companies where he has garnered recognition for his entrepreneurial insight and strategic acumen. Mr. Capovilla currently serves on numerous boards and is Executive Director at Powis Inc.
As President and CEO of Southwall Technologies, an innovative thin film technology company focused on energy efficiency products, Mr. Capovilla restructured and turned around this underperforming company. He revitalized R&D, expanded sales, drove M&A activities and took the company on NASDAQ. He ultimately executed the strategic exit with the successful sale to Solutia; multiplying shareholder value by 5x in a short period of time.
At Palm, Mr. Capovilla restructured the enterprise go-to-market strategy and created a medical vertical for mobile clinical trials. At Fatbrain, a pioneering ecommerce company, Mr. Capovilla oversaw explosive growth and played a key role in the company’s NASDAQ IPO. As President and CEO of Fatbrain, he was named Entrepreneur of the Year for Technology by the Silicon Valley Business Journal in 2000. He later achieved a successful exit for Fatbrain by engineering the sale of the company to Barnes & Noble.
Previous to this role, Mr. Capovilla served as Director of Apple’s Imaging Division where he led a $250M division and held numerous sales leadership positions with the Xerox Corporation.
Co-founder and CEO Wetpaint
Ben Elowitz is co-founder and CEO of Wetpaint, a technology and media company that specializes in building audiences from the social web. The company’s Wetpaint Entertainment news and celebrity website reaches 12 million unique users per month.
Prior to Wetpaint, Mr. Elowitz co-founded Blue Nile (NILE), the largest online retailer of luxury goods; oversaw the $150 million commercial products business for fitness equipment manufacturer Precor; and was also an early employee at Fatbrain.com (FATB), an e-commerce company that went public in 1998 and was sold to Barnes & Noble in 1999.
Mr. Elowitz is a recognized a thought leader on the subject of entrepreneurship and the media industry. He is the author of the Digital Quarters blog and the Media Success newsletter open to senior industry executives only. He has also been an angel investor in various companies such as BetFair (BET:LN), Minted, Cheezburger Networks, and JustFab (IB Holdings); and is a frequent conference speaker on media, social content, and entrepreneurship.
Medical Advisory Board
David T. Durack, M.D., D Phil, FRCP, FRACP, FACP
Chair, Consulting Professor of Medicine, Duke University
Dr. David T. Durack is Consulting Professor of Medicine at Duke University and was previously Senior Vice President, Corporate Medical Affairs and Chief Medical Officer at Becton Dickinson & Co.
Dr. Durack has broad and deep expertise in the area of infectious diseases. He has performed extensive research on the pathogenesis and chemotherapy of bacterial and fungal infections, authoring his doctoral thesis entitled “Experimental Endocarditis” at Oxford University.
Earlier in his clinical career, Dr. Durack was Chief Resident and faculty member in the Department of Medicine at the University of Washington, eventually becoming Chief of the Division of Infectious Diseases and International Health. Following his time at University of Washington, Dr. Durack was Professor of Medicine at Duke University. In addition to his clinical work, Dr. Durack has published more than 230 articles and textbook chapters and co-edited several textbooks.
Dr. Durack is a Fellow of the Royal College of Physicians (UK), the Royal Australasian College of Physicians, and the American College of Physicians. He has been elected to the American Society for Clinical Investigation, the Council of the Infectious Diseases Society of America, and the American Academy of Microbiology. He has served on an FDA Review Panel, the Joint Commission Resources Board of Directors, and as Chairman of the Board, ASM Resources. He is currently a Director for PixelEXX Systems Inc. and has 17 years’ experience as a Medical Affairs functional leader and executive officer in the medical devices and diagnostics industry.
Dr. Durack attended the Correspondence School of West Australia and Scotch College. He earned his medical degree from University of Western Australia and went on to Oxford University as a Rhodes Scholar where he completed his Doctor of Philosophy. Dr. Durack’s internship and residencies were conducted at Radcliffe Infirmary in Oxford and Royal Postgraduate Medical School at Hammersmith Hospital in London.
Franklin R. Cockerill, III, M.D.
CEO of Analyte Health
Dr. Frank Cockerill currently is the CEO of Analyte Health located in Chicago, Illinois. Analyte Health is a leading digital laboratory testing company providing online laboratory services for sexually transmitted diseases.
Dr. Cockerill is the immediate past Chair of Department of Laboratory Medicine and Pathology, Mayo Clinic, and President and CEO of Mayo Collaborative Services, Inc. (MCSI)/Mayo Medical Laboratories (MML). While at Mayo he also carried a named professorship, the Ann and Leo Markin Professor of Medicine and Microbiology at the Mayo Medical School.
Dr. Cockerill is Board Certified in Internal Medicine and Infectious Diseases (American Board of Internal Medicine) and Clinical Microbiology (American Board of Pathology). He practiced Internal Medicine and Infectious Diseases for over a decade before shifting his focus to Clinical Microbiology. Dr. Cockerill’s research interests have ranged from basic discovery to applied science with a special emphasis on the phenotypic and genotypic identification of antimicrobial resistance.
Dr. Cockerill has authored or co-authored over 150 publications in the medical literature many of which relate to diagnostic testing for infectious diseases. He and his research team at Mayo developed numerous real-time PCR assays, which have significant advantages over conventional culture-based assays, and include the first commercially available rapid PCR test for Anthrax. This work has resulted in 8 US patents, 2 foreign patents and 56 licensed technologies.
As President and CEO of Mayo Collaborative Services, Inc. (MCSI), Dr. Cockerill oversaw the largest for-profit company associated with Mayo Clinic. The major service line of MCSI, Mayo Medical Laboratories (MML), is the third largest provider of esoteric laboratory services in the United States and, in total, serves over 4000 clients in 130 countries.
Dr. Cockerill’s current or recent extramural leadership positions include Chair of the Subcommittee on Antimicrobial Susceptibility Testing, Clinical Laboratory Standards Institute (CLSI), Chair, Microbiology Devices Panel of the Medical Devices Advisory Committee of the US Food and Drug Administration (FDA), Board Member and Program Director, of the Association for Molecular Pathology (AMP), Director, American Clinical Laboratory Association Board; Director, Board of Scientific Counselors of the Centers for Disease Control and Prevention (CDC) and Editor, Journal of Clinical Microbiology.
Finally, Dr. Cockerill has received numerous awards, fellowships and honors including the BD Award for Research in Clinical Microbiology, the Laboratory Public Service National Leadership Award and Fellowship in the American Academy of Microbiology. The BD Award, sponsored by the American Society for Microbiology (ASM), is the highest honor bestowed upon a clinical microbiologist in the United States. The Laboratory Public Service National Leadership recognizes significant contributions to the healthcare of the American public with past recipients including both scientists and US senators and congressmen.
Lance Peterson, MD, FASCP, FIDSA, FAAM, FSHEA
Director of Microbiology and Infectious Diseases Research, Vice-Chair of Pathology for Research, NorthShore University HealthSystem
Lance R. Peterson, MD, FASCP, FIDSA, FAAM, FSHEA, is the Director of Microbiology and Infectious Diseases Research, vice-Chair of Pathology for Research, and Epidemiologist at NorthShore University HealthSystem, in Evanston, Illinois. He is also a Clinical Professor at the Pritzker School of Medicine of the University of Chicago, in Chicago, Illinois, and a staff member in the Clinical Microbiology and Infectious Disease Divisions at Evanston Hospital. Dr. Peterson received his MD degree from the University of Minnesota and is certified in Internal Medicine, Infectious Diseases and Medical Microbiology.
His research interests have included the study of infections in the extremities of diabetic patients; investigations of antimicrobial agents in models that simulate closed space, neutropenic infections; the epidemiology of nosocomial pathogens (particularly MRSA, enterococci, MDR Gram negative bacteria, and Clostridium difficile); the development and evaluation of molecular diagnostic testing; measuring activity of new antimicrobial compounds against bacteria and fungi; and the study of the molecular mechanisms for the resistance of staphylococci and pneumococci to the new fluoroquinolone antimicrobial agents. Current research activities focus on using molecular testing methods to enhance infection control activities; understanding the regulation of antimicrobial agent resistance in staphylococci and Enterobacteriaceae; designing novel strategies for treatment of infections due to resistant bacteria; testing innovations to reduce catheter-related bloodstream infections; and developing new diagnostic tests for rapidly detecting antibiotic resistant bacterial pathogens. He has over 700 scientific publications/presentations and is recognized in the 21st Century editions of Marquis’ Who’s Who.
William J. McDaniel, M.D.
Rear Admiral, U.S. Navy (ret)
Dr. McDaniel was born on a farm near Muskogee, Oklahoma and attended college on a full wrestling scholarship at Oklahoma State University where he received a Bachelor of Science degree in Physiology. Following graduation, he began studies at the University of Oklahoma School of Medicine and received his Doctor of Medicine degree in 1968. He completed his internship at St. Francis Hospital in Tulsa, Oklahoma in 1969.
After commissioning in the Navy in 1969, Dr. McDaniel served in a variety of locations, including Vietnam, Spain, Japan, Korea, and Hawaii over the course of 30 years. He had a total of five commands, assuming command of Naval Hospital, Charleston, South Carolina, in 1988, which became a key medical facility during Hurricane Hugo in 1989. He was selected as Rear Admiral in 1989. In June, 1990, he became the Surgeon for the U.S. Pacific Command, Camp H.M. Smith, Hawaii. In 1992 he assumed command of the Naval Medical Center, Portsmouth, Virginia, and received his second star there in 1993.
Since retiring from the navy in January, 1997, Dr. McDaniel has worked as a consultant or board member for multiple organizations, including Imatron, Inc.; Center for Naval Analysis; Chairman of a Flag/General Advisory Board to the Applied Physics Laboratory, Johns Hopkins University; and, as a consultant to the Under Secretary of Defense for Personnel and Readiness, the Honorable Rudy de Leon. He served on the U.S. Olympic Committee as the co-chairman for the Sports Medicine 2000 committee from 1997-2000, and was the physician for the U.S. Freestyle Wrestling team in the World Championships in Ankara, Turkey, in 1999, and for the World Cup Freestyle Championships in 2000. He was the Chairman of a Blue Ribbon Panel formed by the CNO for the assessment of the future of National Naval Medical Center, Bethesda, MD, in 2000.
Following the tragedy of 9/11, he became the federal liaison for Johns Hopkins University in preparing their Homeland Security plan. He was a consultant for EADS North America on development of field medical hospitals, and was a part time consultant for EAI Corporation and for Northrup Grumman. He was on the Board of Advisors for Aetna Insurance Company of Hartford, CT, from 2007-2010. He is currently a Board member for Computer Technology Associates, on the Board of Advisors of Haven Behavioral Healthcare, Inc., and on the Board of Directors for Vioguard, Inc., of Seattle, WA. He is Chairman of the Board for DEEC (Diesel Engine Emission Control) of Bellevue, Wa.
Dr. McDaniel was hired by the Commander-in-Chief of the Pacific Fleet in Hawaii to head the advance team into Banda Aceh following the tsunami of December, 2004, preceding USNS Mercy’s arrival. He spent 2 months in Banda Aceh working on issues of public health, then spent almost another month working on Nias Island, Indonesia, following the earthquake there. He has been an extremely active lecturer around the nation about this activity, strongly supporting a movement to continue using military medical assets for medical assist visits around the world. He has given multiple lectures on leadership around the US. He has authored a book about that experience, “Faces of the Tsunami,” which is currently in the process of publication.
Daniel J. Sexton, M.D.
Professor of Medicine, Duke University
Dr. Sexton is a graduate of the Northwestern University School of Medicine and is currently a Professor of Medicine at the Duke University School of Medicine.
Early in his career, Dr. Secton spent two years as an Epidemic Intelligence Service Officer at the CDC. In addition to 11 years of experience in private practice in Oklahoma City, Dr. Sexton also worked at Monash Medical Center in Melbourne Australia while on sabbatical in 1989. He was made an honorary lifetime member of the Australasian Society for Infectious Diseases in 2006.
Dr. Sexton has had a direct role in the training of numerous medical students, residents, fellows and postdoctoral students during the 26 years he has been on the Duke faculty. Fourteen of 20 fellows who worked under Dr. Sexton’s supervision are currently hospital epidemiologists and active in research related to HAIs.
Dr. Sexton is one of five Editors in Chief of the Infectious Disease section of UpToDate. He has published more than 200 peer reviewed original manuscripts. He is a recipient of the Clinician Award from the Infectious Diseases Society of America and was previously the Chair of the IDSA Clinical Affairs Committee and served on the IDSA Board of Directors and the Board of the National Foundation for Infectious Diseases.
Dr. Secton has received the Golden Apple Teaching Award from the Duke University School of Medicine, a Golden Apple Award from the American Medical School Student Association, The Eugene Stead Award for Excellence in Teaching from the Duke Medicine Housestaff (twice) and was named a Master Clinician Teacher by the Duke University School of Medicine in 2011.
Dr. Sexton’s multiple research interests include the risk factors, outcomes and definition of healthcare-associated bloodstream and surgical site infections, risk factors and outcomes of infections due to Staphylococcus aureus and criteria, outcomes and complications of infective endocarditis. He founded the Duke Infection Control Outreach Network in 1997 that has since grown to include 43 community hospitals in 6 states. Dr. Sexton is currently the principal investigator on one of 5 epicenter grants awarded by the Centers for Disease Control, and the PI for grants from The Duke Foundation and the CDC Foundation related to the Duke Antimicrobial Stewardship Outreach network which he founded in 2013.